FDA Accelerates Atacicept Review for Full Approval in IgA Nephropathy
VERA sits 83% above its 52-week low of $18.79.
Summary
Vera Therapeutics announced alignment with the FDA on an earlier analysis plan for its ORIGIN Phase 3 trial of atacicept in IgA Nephropathy (IgAN). This follows an 8-K filing and means eGFR results are now expected in Q3 2026, potentially enabling a full approval submission (sBLA) in Q4 2026. This significantly accelerates the regulatory pathway for the company's lead drug candidate, reducing time to market and de-risking the program. The market will be watching for the eGFR results in Q3 2026.
At the time of this announcement, VERA was trading at $34.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.79 to $56.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.